Innate Pharma SA (NASDAQ:IPHA) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET

Company Participants

Henry Wheeler - VP and Head of IR

Mondher Mahjoubi - Chairman of Executive Board and CEO

Joyson Karakunnel - Executive VP and Chief Medical Officer

Yannis Morel - Executive VP of Product Portfolio Strategy and Business Development and Member of Executive Board

Conference Call Participants

Daina Graybosch - SVB Leerink

Olga Smolentseva - Bryan Garnier

Jingming Chen - Evercore

Arthur He - H.C. Wainwright

Operator

Good morning, everyone. My name is Juan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Innate Pharma First Quarter 2022 Business Update. [Operator Instructions]

I will now introduce to Mr. Henry Wheeler, Head of Investor Relations. Please Mr. Wheeler, go ahead.

Henry Wheeler

Thank you. Good morning and good afternoon and welcome everyone. This morning Innate issued a press release providing a business update for our first quarter '22 results. We look forward to highlighting the progress made during the quarter as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website.

On Slide 2, before we start, I would like to remind you that we will make forward looking statements regarding the financial outlook, in addition to regulatory and product plan developments. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.

On Slide 3, on today's call, we will be joined by Mondher Mahjoubi, our Chief Executive Officer who will then hand over to Joyson Karakunnel, EVP and Chief Medical Officer and Yannis Morel, EVP of Business Development and Product Portfolio Strategy.

And we will also have our CFO Frederic Lombard on for Q&A. Mondher, I'll now hand over to you.

Mondher Mahjoubi

Thank you, Henry. Good morning, good afternoon, everyone. And thank you for joining this call. Please move to Slide 4 and let me first start by reminding you of our strategy. Our strategy centers around 3 key priorities where we look to drive value from our early R&D efforts for later sales partnership and it makes sense to do so.

First, we look to create near-term value driven by our lead proprietary candidate, lacutamab, which is in development for T-cell lymphoma, which is opened in all-comers cohort in mycosis fungoides in the TELLOMAK trials. And also initiated 2 trials in the larger indication of peripheral T-cell lymphoma.